LONN Stock Analysis: Lonza | SW
Diagnostics & Research | SW, Switzerland | Market Cap: 37.870m CHF | 12M Return: 0% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 90.0M
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lonza Group AG is a Switzerland-based contract development and manufacturing organization (CDMO) that provides outsourced services to pharmaceutical and biotechnology companies across global markets. Founded in 1897 and headquartered in Basel, the company operates through three segments: Integrated Biologics, which covers clinical-to-commercial biologics manufacturing using mammalian and drug product platforms; Advanced Synthesis, which produces small molecules, antibody-drug conjugates (ADCs), bioconjugates, and highly potent active pharmaceutical ingredients; and Specialized Modalities, which spans cell and gene therapy, microbial fermentation, bioscience, and mRNA technologies.
As a CDMO, Lonzas business model enables drug developers to outsource manufacturing capacity and specialized technical expertise rather than build in-house production. The CDMO sector has grown as demand rises for complex biologics and advanced therapies, which typically require specialized facilities, process development capabilities, and regulatory know-how that most sponsor companies prefer to access through external partners.
- Biologics CDMO demand drives Integrated Biologics revenue growth
- ADC manufacturing capacity expansion captures oncology outsourcing surge
- Biotech funding recovery strengthens CDMO order pipeline
| Net Income: -110.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.31 > 1.0 |
| NWC/Revenue: 43.67% < 20% (prev 20.27%; Δ 23.40% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.44b > Net Income -110.0m |
| Net Debt (4.04b) to EBITDA (1.97b): 2.05 < 3 |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.9m) vs 12m ago -2.00% < -2% |
| Gross Margin: 35.79% > 18% (prev 32.93%; Δ 2.85% > 0.5%) |
| Asset Turnover: 34.15% > 50% (prev 37.72%; Δ -3.57% > 0%) |
| Interest Coverage Ratio: 9.69 > 6 (EBIT TTM 1.37b / Interest Expense TTM 141.0m) |
| A: 0.15 (Total Current Assets 6.94b - Total Current Liabilities 4.17b) / Total Assets 18.3b |
| B: 0.50 (Retained Earnings 9.10b / Total Assets 18.3b) |
| C: 0.07 (EBIT TTM 1.37b / Avg Total Assets 18.5b) |
| D: 0.80 (Book Value of Equity 8.12b / Total Liabilities 10.1b) |
| Altman-Z'' = 3.96 = AA |
| DSRI: 1.19 (Receivables 1.92b/1.80b, Revenue 6.33b/7.09b) |
| GMI: 0.92 (GM 32.93% / 35.79%) |
| AQI: 0.51 (AQ_t 0.15 / AQ_t-1 0.30) |
| SGI: 0.89 (Revenue 6.33b / 7.09b) |
| TATA: -0.09 (NI -110.0m - CFO 1.44b) / TA 18.3b) |
| Beneish M = -3.32 (Cap -4..+1) = AA |
As of July 28, 2026, the stock is trading at CHF 559.40 with a total of 183,605 shares traded. Over the past week, the price has changed by -0.99%, over one month by +3.67%, over three months by +15.69% and over the past year by +0.01%.
Current recommended Stop Loss: 543.30 (which is 2.9% or 1.2 ATR below the current price).
Lonza has no consensus analysts rating.
P/E Trailing = 34.6012
P/E Forward = 29.9401
P/S = 5.5115
P/B = 4.6138
P/EG = 1.5763
Revenue TTM = 6.33b CHF
EBIT TTM = 1.37b CHF
EBITDA TTM = 1.97b CHF
Long Term Debt = 3.39b CHF (from longTermDebt, last quarter)
Short Term Debt = 774.0m CHF (from shortTermDebt, last quarter)
Debt = 4.52b CHF (from shortLongTermDebtTotal, last quarter) + Leases 355.0m
Net Debt = 4.04b CHF (calculated: Debt 4.52b - CCE 487.0m)
Enterprise Value = 41.9b CHF (37.9b + Debt 4.52b - CCE 487.0m)
Interest Coverage Ratio = 9.69 (Ebit TTM 1.37b / Interest Expense TTM 141.0m)
EV/FCF = 257.1x (Enterprise Value 41.9b / FCF TTM 163.0m)
FCF Yield = 0.39% (FCF TTM 163.0m / Enterprise Value 41.9b)
FCF Margin = 2.58% (FCF TTM 163.0m / Revenue TTM 6.33b)
Net Margin = -1.74% (Net Income TTM -110.0m / Revenue TTM 6.33b)
Gross Margin = 35.79% ((Revenue TTM 6.33b - Cost of Revenue TTM 4.06b) / Revenue TTM)
Gross Margin QoQ = 38.38% (prev 32.83%)
Tobins Q-Ratio = 2.30 (Enterprise Value 41.9b / Total Assets 18.3b)
Interest Expense / Debt = 3.12% (Interest Expense 141.0m / Debt 4.52b)
Taxrate = 17.83% (229.0m / 1.28b)
NOPAT = 1.12b (EBIT 1.37b * (1 - 17.83%))
Current Ratio = 1.66 (Total Current Assets 6.94b / Total Current Liabilities 4.17b)
Debt / Equity = 0.56 (Debt 4.52b / totalStockholderEquity, last quarter 8.12b)
Debt / EBITDA = 2.05 (Net Debt 4.04b / EBITDA 1.97b)
Debt / FCF = 24.75 (Net Debt 4.04b / FCF TTM 163.0m)
Total Stockholder Equity = 8.80b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.59% (Net Income -110.0m / Total Assets 18.3b)
RoE = -1.25% (Net Income TTM -110.0m / Total Stockholder Equity 8.80b)
RoCE = 11.20% (EBIT 1.37b / Capital Employed (Equity 8.80b + L.T.Debt 3.39b))
RoIC = 7.72% (NOPAT 1.12b / Invested Capital 14.5b)
WACC = 6.89% (E(37.9b)/V(42.4b) * Re(7.41%) + D(4.52b)/V(42.4b) * Rd(3.12%) * (1-Tc(0.18)))
Discount Rate = 7.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.88 | Cagr: -2.73%
[DCF] Terminal Value 75.44% ; FCFF base≈163.0m ; Y1≈163.7m ; Y5≈173.4m
[DCF] Fair Price = N/A (negative equity: EV 2.70b - Net Debt 4.04b = -1.34b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -41.71 | Revenue CAGR: -1.68% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=18.77 | Chg30d=+2.73% | Revisions=+22% | GrowthEPS=+24.9% | GrowthRev=+9.2%
EPS next Year (2027-12-31): EPS=21.82 | Chg30d=-0.11% | Revisions=+22% | GrowthEPS=+16.2% | GrowthRev=+12.0%
[Analyst] Revisions Ratio: +27% (up=8, down=4)